2.Combined modality therapy in the adjuvant treatment of uterine serous carcinoma.
Journal of Gynecologic Oncology 2016;27(2):e13-
No abstract available.
Chemotherapy, Adjuvant
;
Combined Modality Therapy
;
*Cystadenocarcinoma, Serous
;
Humans
;
Neoplasm Staging
;
*Uterine Neoplasms
3.DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer.
Mi Kyung KIM ; In Ho LEE ; Ki Heon LEE ; Yoo Kyung LEE ; Kyeong A SO ; Sung Ran HONG ; Chang Sun HWANG ; Mee Kyung KEE ; Jee Eun RHEE ; Chun KANG ; Soo Young HUR ; Jong Sup PARK ; Tae Jin KIM
Journal of Gynecologic Oncology 2016;27(2):e14-
OBJECTIVE: DNA methylation has been shown to be a potential biomarker for early cancer detection. The aim of this study was to evaluate DNA methylation profiles according to liquid-based Pap (LBP) test results and to assess their diagnostic value in a Korean population. METHODS: A total of 205 patients with various Papanicolaou test results were enrolled to this study (negative, 26; atypical squamous cells of undetermined significance, 39; low grade squamous intraepithelial lesion, 44; high grade squamous intraepithelial lesion (HSIL), 48; and cancer, 48). DNA methylation analysis of four genes, ADCYAP1, PAX1, MAL, and CADM1, was performed on residual cervical cells from LBP samples using a quantitative bisulfite pyrosequencing method. To evaluate the diagnostic performance of the four methylated genes for cancer detection, receiver operating characteristic (ROC) curves were drawn. Sensitivities and specificities were also tested at cutoffs determined from the ROC curves. RESULTS: Cervical cancer cells showed dramatically increased methylation levels for the four genes analyzed. ADCYAP1 and PAX1 also trended toward elevated methylation levels in HSIL samples, although the levels were much lower than those in cancer cells. The sensitivities of methylated ADCYAP1, PAX1, MAL, and CADM1 for the detection of cancer were 79.2%, 75.0%, 70.8%, and 52.1%, and the specificities were 92.0%, 94.0%, 94.7%, and 94.0%, respectively. Methylated ADCYAP1 and PAX1 demonstrated relatively better discriminatory ability than did methylated MAL and CADM1 (area under the curves 0.911 and 0.916 vs. 0.854 and 0.756, respectively). CONCLUSION: DNA methylation status, especially in the ADCYAP1 and PAX1 genes, showed relatively good specificity, ranging from 90% to 94%. The possible additive and complementary roles of DNA methylation testing with respect to conventional cervical cancer screening programs will need to be validated in prospective population-based studies.
Alphapapillomavirus/genetics
;
*Atypical Squamous Cells of the Cervix/pathology/virology
;
Cell Adhesion Molecules/genetics
;
*DNA Methylation
;
Female
;
Genotype
;
Humans
;
Immunoglobulins/genetics
;
Myelin and Lymphocyte-Associated Proteolipid Proteins/genetics
;
Paired Box Transcription Factors/genetics
;
Papanicolaou Test
;
Pituitary Adenylate Cyclase-Activating Polypeptide/genetics
;
ROC Curve
;
Squamous Intraepithelial Lesions of the Cervix/*genetics/pathology/virology
;
Uterine Cervical Neoplasms/*genetics/pathology/virology
;
Vaginal Smears
4.Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
Hyun Hoon CHUNG ; Seo Young KANG ; Seunggyun HA ; Jae Weon KIM ; Noh Hyun PARK ; Yong Sang SONG ; Gi Jeong CHEON
Journal of Gynecologic Oncology 2016;27(2):e15-
OBJECTIVE: We investigated the prognostic value of intratumoral [18F]fluorodeoxyglucose (FDG) uptake heterogeneity (IFH) derived from positron emission tomography/computed tomography (PET/CT) in patients with cervical cancer. METHODS: Patients with uterine cervical cancer of the International Federation of Obstetrics and Gynecology (FIGO) stage IB to IIA were imaged with [18F]FDG PET/CT before radical surgery. PET/CT parameters such as maximum and average standardized uptake values (SUV(max) and SUV(avg)), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and IFH were assessed. Regression analyses were used to identify clinicopathological and imaging variables associated with progression-free survival (PFS). RESULTS: We retrospectively reviewed clinical data of 85 eligible patients. Median PFS was 32 months (range, 6 to 83 months), with recurrence observed in 14 patients (16.5%). IFH at an SUV of 2.0 was correlated with primary tumor size (p<0.001), SUV(tumor) (p<0.001), MTV(tumor) (p<0.001), TLG(tumor) (p<0.001), depth of cervical invasion (p<0.001), and negatively correlated with age (p=0.036). Tumor recurrence was significantly associated with TLG(tumor) (p<0.001), MTV(tumor) (p=0.001), SUV(LN) (p=0.004), IFH (p=0.005), SUV(tumor) (p=0.015), and FIGO stage (p=0.015). Multivariate analysis identified that IFH (p=0.028; hazard ratio, 756.997; 95% CI, 2.047 to 279,923.191) was the only independent risk factor for recurrence. The Kaplan-Meier survival graphs showed that PFS significantly differed in groups categorized based on IFH (p=0.013, log-rank test). CONCLUSION: Preoperative IFH was significantly associated with cervical cancer recurrence. [18F]FDG based heterogeneity may be a useful and potential predicator of patient recurrence before treatment.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Squamous Cell/metabolism/*radionuclide imaging/secondary
;
Disease-Free Survival
;
Female
;
Fluorodeoxyglucose F18/*pharmacokinetics
;
Glycolysis
;
Humans
;
Middle Aged
;
Multimodal Imaging
;
Neoplasm Invasiveness
;
Neoplasm Recurrence, Local/metabolism/radionuclide imaging
;
Neoplasm Staging
;
*Positron-Emission Tomography
;
Predictive Value of Tests
;
Radiopharmaceuticals/*pharmacokinetics
;
Retrospective Studies
;
Tomography, X-Ray Computed
;
Tumor Burden
;
Uterine Cervical Neoplasms/metabolism/pathology/*radionuclide imaging
5.Details of recurrence sites after definitive radiation therapy for cervical cancer.
Reiko KOBAYASHI ; Hideomi YAMASHITA ; Kae OKUMA ; Kuni OHTOMO ; Keiichi NAKAGAWA
Journal of Gynecologic Oncology 2016;27(2):e16-
OBJECTIVE: This is a retrospective study aimed at clarifying the details of recurrence patterns and sites in patients with cervical cancer treated with definitive radiation therapy (RT). METHODS: Data were analyzed from consecutive patients, admitted to the University of Tokyo Hospital (Tokyo, Japan) between 2001 and 2013, who had received definitive RT, with or without chemotherapy, for International Federation of Gynecology and Obstetrics stages IB-IVA cervical cancer. RESULTS: One hundred and thirty-seven patients formed the patient cohort. The median follow-up period for surviving patients was 57.0 months. A complete response was achieved in 121 patients (88%). Of these, 36 (30%) developed a cancer recurrence during follow-up. The first sites of recurrence were located in intra-RT fields in nine, outside RT fields in 20, and both in seven patients. In the intra-RT field group, all patients showed a local recurrence, while no one experienced an isolated pelvic lymph node (PLN) recurrence. In the outside RT field group, the most frequent site of recurrence was lung (60%), and three-quarters of patients were free from intra-RT field recurrence until the last follow-up. Of the entire cohort, including 48 PLN-positive patients, only seven patients (5.1%) developed PLN persistence or recurrence, all in the common iliac, internal iliac, and/or obturator nodes, and all with another synchronous relapse. CONCLUSION: Local disease was a major type of intra-RT field recurrence, while PLN control was favorable even in initially PLN-positive patients. The predominance of outside RT field recurrence alone highlights issues concerning distant control, including the intensity enhancement of systematic therapy.
Adenocarcinoma/drug therapy/*radiotherapy/secondary
;
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/therapeutic use
;
Brachytherapy
;
Carcinoma, Squamous Cell/drug therapy/*radiotherapy/secondary
;
Chemoradiotherapy
;
Disease-Free Survival
;
Dose Fractionation
;
Female
;
Follow-Up Studies
;
Humans
;
Lung Neoplasms/*secondary
;
Lymphatic Metastasis
;
Middle Aged
;
Neoplasm Recurrence, Local/*diagnosis
;
Pelvis
;
Retrospective Studies
;
Survival Rate
;
Uterine Cervical Neoplasms/drug therapy/pathology/*radiotherapy
6.Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09).
Ji Hyun CHANG ; Won Il JANG ; Yong Bae KIM ; Jin Hee KIM ; Young Seok KIM ; Yeon Sil KIM ; Won PARK ; Juree KIM ; Won Sup YOON ; Joo Young KIM ; Hak Jae KIM
Journal of Gynecologic Oncology 2016;27(2):e17-
OBJECTIVE: To assess the outcome of the treatment of primary vaginal cancer using definitive radiotherapy (RT) and to evaluate the prognostic factors of survival. METHODS: The medical records of nine institutions were retrospectively reviewed to find the patients with vaginal cancer treated with definitive RT with or without chemotherapy. A total of 138 patients met the inclusion criteria. None had undergone curative excision. RESULTS: The median follow-up time of the survivors was 77.6 months and the median survival time was 46.9 months. The 5-year overall survival, cancer-specific survival (CSS), and progression-free survival (PFS) rates were 68%, 80%, and 68.7%, respectively. In the survival analysis, the multivariate analysis showed that a lower the International Federation of Gynecology and Obstetrics (FIGO) stage and prior hysterectomy were favorable prognostic factors of CSS, and a lower FIGO stage and diagnosed prior to year 2000 were favorable prognostic factors of PFS. In the subgroup analysis of the patients with available human papillomavirus (HPV) results (n=27), no statistically significant relationship between the HPV status and recurrence or survival was found. Grade 3 or 4 acute and late toxicity were present in 16 and 9 patients, respectively. The FIGO stage and the tumor size were predictors of severe late toxicity. CONCLUSION: The data clearly showed that a higher FIGO stage was correlated with a worse survival outcome and higher severe late toxicity. Therefore, precise RT and careful observation are crucial in advanced vaginal cancer. In this study, the HPV status was not related to the survival outcome, but its further investigation is needed.
Adult
;
Aged
;
Aged, 80 and over
;
Brachytherapy
;
Carcinoma, Squamous Cell/mortality/*radiotherapy/secondary/virology
;
Chemoradiotherapy
;
Disease-Free Survival
;
Female
;
Follow-Up Studies
;
Humans
;
Hysterectomy
;
Middle Aged
;
Neoplasm Staging
;
Papillomavirus Infections/diagnosis
;
Radiotherapy/adverse effects
;
Republic of Korea
;
Retrospective Studies
;
Survival Rate
;
Treatment Outcome
;
Tumor Burden
;
Vaginal Neoplasms/mortality/pathology/*radiotherapy/virology
7.Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Jun ZHU ; Hao WEN ; Rui BI ; Xiaohua WU
Journal of Gynecologic Oncology 2016;27(2):e18-
OBJECTIVE: Uterine carcinosarcoma (UCS) shared the same staging system with endometrial carcinoma in the International Federation of Gynecology and Obstetrics 2009. The aim of the present study was to compare the clinicopathological and prognostic characteristics between UCS and grade 3 endometrioid endometrial carcinoma (G3EC). METHODS: A retrospective analysis of 60 UCS and 115 G3EC patients with initial treatment at the Department of Gynecology in the Fudan University Shanghai Cancer Center between February 2006 and August 2013. Chi-square analysis was used to compare differences between variables. Prognostic factors were determined using univariate/multivariate analysis, and the survival rates were assessed using the Kaplan-Meier method. The Cox regression model was used to assess the independent prognostic factor. RESULTS: UCS had significantly worse overall survival (OS) compared with G3EC. Carcinosarcoma subtype was an independent factor (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.0 to 5.8; p=0.039), stratified based on stage. Compared with G3EC, UCS patients had a greater incidence of ascites fluid (55.0% vs. 15.7%, p<0.001) and adnexal involvement (20.0% vs. 8.7%, p=0.048) and larger median tumor volume (4.6 cm vs. 4.0 cm, p=0.046). Subgroup analysis of the prognostic factors revealed that UCS patients exhibited worse OS than G3EC patients in such specific subgroups as patients at younger ages, with postmenopausal status, without ascites fluid, with early stage diseases, without vagina invasion, without lymph node metastases and receiving adjuvant chemo/radiotherapy. Adjuvant radiotherapy with chemotherapy was predictive of better survival in UCS patients compared with chemotherapy or radiotherapy alone (5-year OS, 71.0% vs. 35.8%, p=0.028). Multivariate Cox regression revealed that tumor mesenchymal component (HR, 4.6; 95% CI, 1.4 to 15.8; p=0.014) was an independent prognostic factor for UCS, whereas advanced stages (HR, 5.9; 95% CI, 1.0 to 33.9; p=0.046) and ascites fluid (HR, 5.1; 95% CI, 1.1 to 22.7; p=0.032) were independently correlated with poor prognosis for G3EC patients. CONCLUSION: The distinctions in both clinicopathological and prognostic characteristics between UCS and G3EC suggest that this subtype should be treated separately from high-risk epithelial endometrial carcinoma.
Adnexa Uteri/pathology
;
Adult
;
Age Factors
;
Aged
;
Aged, 80 and over
;
Aorta
;
Ascites/etiology
;
Carcinoma, Endometrioid/*secondary/*therapy
;
Carcinosarcoma/*secondary/*therapy
;
Chemotherapy, Adjuvant
;
Cytoreduction Surgical Procedures
;
Endometrial Neoplasms/*pathology/*therapy
;
Female
;
Humans
;
Hysterectomy
;
*Lymph Node Excision
;
Lymphatic Metastasis
;
Middle Aged
;
Neoplasm Grading
;
Neoplasm Invasiveness
;
Neoplasm Staging
;
Pelvis
;
Postmenopause
;
Radiotherapy, Adjuvant
;
Retrospective Studies
;
Survival Rate
;
Tumor Burden
;
Vagina/pathology
8.The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone.
Haider MAHDI ; Benjamin NUTTER ; Fadi ABDUL-KARIM ; Sudha AMARNATH ; Peter G ROSE
Journal of Gynecologic Oncology 2016;27(2):e19-
OBJECTIVE: To investigate the impact of pelvic radiation on survival in patients with uterine serous carcinoma (USC) who received adjuvant chemotherapy. METHODS: Patients with stage I-IV USC were identified from the Surveillance, Epidemiology, and End Results program 2000 to 2009. Patients were included if treated with surgery and chemotherapy. Patients were divided into two groups: those who received chemotherapy and pelvic radiation therapy (CT_RT) and those who received chemotherapy only (CT). Kaplan-Meier curves and Cox regression proportional hazard models were used. RESULTS: Of the 1,838 included patients, 1,272 (69%) were CT and 566 (31%) were CT_RT. Adjuvant radiation was associated with significant improvement in overall survival (OS; p<0.001) and disease-specific survival (DSS; p<0.001) for entire cohort. These findings were consistent for the impact of radiation on OS (p<0.001) and DSS (p<0.001) in advanced stage (III-IV) disease but not for early stage (I-II) disease (p=0.21 for OS and p=0.82 for DSS). In multivariable analysis adjusting for age, stage, race and extent of lymphadenectomy, adjuvant radiation was a significant predictor of OS and DSS for entire cohort (p=0.003 and p=0.05) and in subset of patients with stage III (p=0.02 and p=0.07) but not for patients with stage I (p=0.59 and p=0.49), II (p=0.83 and p=0.82), and IV USC (p=0.50 and p=0.96). Other predictors were stage, positive cytology, African American race and extent of lymphadenectomy. CONCLUSION: In USC patients who received adjuvant chemotherapy, adjuvant radiation was associated with significantly improved outcome in stage III disease but not for other stages. Positive cytology, extent of lymphadenectomy and African race were significant predictors of outcome.
Adult
;
African Americans/statistics & numerical data
;
Aged
;
Aged, 80 and over
;
Carcinoma, Papillary/pathology/radiotherapy/*therapy
;
Chemoradiotherapy, Adjuvant
;
Chemotherapy, Adjuvant
;
Female
;
Humans
;
Hysterectomy
;
*Lymph Node Excision
;
Middle Aged
;
Neoplasm Staging
;
SEER Program
;
Survival Rate
;
Uterine Neoplasms/pathology/radiotherapy/*therapy
9.Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer.
Jin Young PARK ; Eun Jin HEO ; Jeong Won LEE ; Yoo Young LEE ; Tae Joong KIM ; Byoung Gie KIM ; Duk Soo BAE
Journal of Gynecologic Oncology 2016;27(2):e20-
OBJECTIVE: Fertility-sparing surgery (FSS) is becoming an important technique in the surgical management of young women with early-stage epithelial ovarian cancer (EOC). We retrospectively evaluated the outcome of laparoscopic FSS in presumed clinically early-stage EOC. METHODS: We retrospectively searched databases of patients who received laparoscopic FSS for EOC between January 1999 and December 2012 at Samsung Medical Center. Women aged < or =40 years were included. The perioperative, oncological, and obstetric outcomes of these patients were evaluated. RESULTS: A total of 18 patients was evaluated. The median age of the patients was 33.5 years (range, 14 to 40 years). The number of patients with clinically stage IA and IC was 6 (33.3%) and 12 (66.7%), respectively. There were 7 (38.9%), 5 (27.8%), 3 (16.7%), and 3 patients (16.7%) with mucinous, endometrioid, clear cell, and serous tumor types, respectively. Complete surgical staging to preserve the uterus and one ovary with adnexa was performed in 4 patients (22.2%). Two out of them were upstaged to The International Federation of Gynecology and Obstetrics stage IIIA1. During the median follow-up of 47.3 months (range, 11.5 to 195.3 months), there were no perioperative or long term surgical complications. Four women (22.2%) conceived after their respective ovarian cancer treatments. Three (16.7%) of them completed full-term delivery and one is expecting a baby. One patient had disease recurrence. No patient died of the disease. CONCLUSION: FSS in young patients with presumed clinically early-stage EOC is a challenging and cautious procedure. Further studies are urgent to determine the safety and feasibility of laparoscopic FSS in young patients with presumed clinically early-stage EOC.
Adolescent
;
Adult
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Female
;
*Fertility Preservation
;
Humans
;
Laparoscopy
;
Live Birth
;
Neoplasm Recurrence, Local/blood/diagnosis/*therapy
;
Neoplasm Staging
;
Neoplasms, Glandular and Epithelial/drug therapy/*pathology/*surgery
;
*Organ Sparing Treatments
;
Ovarian Neoplasms/drug therapy/*pathology/*surgery
;
Pregnancy
;
Pregnancy Rate
;
Retrospective Studies
;
Term Birth
;
Treatment Outcome
;
Young Adult
10.Clinical significance of human papillomavirus genotyping.
Journal of Gynecologic Oncology 2016;27(2):e21-
Cervical cancer is the fourth most common cancer in women worldwide, and the human papillomavirus (HPV) is the main causative agent for its development. HPV is a heterogeneous virus, and a persistent infection with a high-risk HPV contributes to the development of cancer. In recent decades, great advances have been made in understanding the molecular biology of HPV, and HPV\'s significance in cervical cancer prevention and management has received increased attention. In this review, we discuss the role of HPV genotyping in cervical cancer by addressing: clinically important issues in HPV virology; the current application of HPV genotyping in clinical medicine; and potential future uses for HPV genotyping.
DNA, Viral/*analysis
;
Early Detection of Cancer/*methods
;
Female
;
*Genome, Viral
;
Genotype
;
Humans
;
Papillomaviridae/classification/*genetics
;
Papillomavirus Infections/complications/drug therapy/*virology
;
Papillomavirus Vaccines/therapeutic use
;
Uterine Cervical Neoplasms/diagnosis/drug therapy/*virology